Losartan potassium mechanism of action
Pro Research Analysisby 
Searched over 200M research papers
Angiotensin II Receptor Blockade: Core Mechanism of Losartan Potassium
Losartan potassium works mainly by blocking the angiotensin II type 1 (AT1) receptor. Angiotensin II is a hormone that causes blood vessels to constrict, leading to increased blood pressure. By blocking the AT1 receptor, losartan prevents angiotensin II from exerting its effects, resulting in blood vessel relaxation and lower blood pressure. This mechanism is highly specific and is the primary reason losartan is effective in treating hypertension and related conditions Burnier1995Mcintyre1997.
Role of Active Metabolite and Renin–Angiotensin System Modulation
Losartan’s effectiveness is largely due to its active metabolite, E3174, which sustains the blockade of the renin–angiotensin system. This blockade leads to an increase in plasma renin activity and angiotensin II levels, as the body tries to compensate for the blocked receptors. At higher doses, losartan can also decrease plasma aldosterone levels, further contributing to its blood pressure-lowering effects .
Additional Mechanisms: Inflammation and Organ Protection
Beyond blood pressure control, losartan has been shown to reduce inflammation by decreasing levels of inflammatory cytokines such as IL-1β and TNF-α, particularly in nerve tissues. This anti-inflammatory action may help alleviate pain in conditions like chemotherapy-induced neuropathy . In kidney injury models, losartan (especially when delivered via nanoparticles) improves kidney function and reduces tissue damage by inhibiting the NF-kB pathway and lowering ET-1 expression, which are both involved in inflammation and fibrosis .
Effects on Other Systems: Intraocular Pressure and Gastrointestinal Motility
Losartan also reduces intraocular pressure, not by lowering blood pressure, but by specifically affecting the renin–angiotensin system within the eye. This suggests a direct local effect on fluid regulation in ocular tissues . In the gastrointestinal system, losartan modulates smooth muscle tone, likely by interfering with cholinergic pathways, which may explain some of its gastrointestinal side effects such as diarrhea or constipation .
Potential Interaction with ACE
Recent research suggests that losartan may also interact with the angiotensin-converting enzyme (ACE), potentially blocking its activity and affecting intracellular signaling. This adds another layer to its mechanism, although this effect is less well understood compared to its primary action on the AT1 receptor .
Conclusion
Losartan potassium primarily lowers blood pressure by selectively blocking the angiotensin II type 1 receptor, preventing the hormone’s vasoconstrictive and aldosterone-secreting effects. Its active metabolite ensures sustained action, and additional benefits include anti-inflammatory effects, organ protection, and modulation of intraocular and gastrointestinal functions. Emerging evidence also points to possible interactions with ACE, broadening our understanding of losartan’s pharmacological actions Burnier1995Kim2019Bezerra2022+4 MORE.
Sources and full results
Most relevant research papers on this topic
Losartan as an ACE inhibitor: a description of the mechanism of action through quantum biochemistry
Losartan effectively treats hypertension by blocking the activity of the angiotensin I-converting enzyme, revealing a new mechanism of action for its treatment.
Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension.
Losartan potassium is an effective and safe treatment for essential hypertension, with potential benefits for elderly, liver disease, and renal impairment patients.
Effect of oral losartan potassium administration on intraocular pressure in normotensive and glaucomatous human subjects.
Losartan potassium effectively reduces intraocular pressure without affecting blood pressure, confirming the role of the renin-angiotensin system in regulating intraocular pressure in humans.
Modulating effect of losartan potassium on the mutagenicity and recombinogenicity of doxorubicin in somatic cells of Drosophila melanogaster.
Losartan potassium does not have a mutagenic effect on Drosophila melanogaster cells, but when combined with doxorubicin, it reduces the number of mutant spots without altering the recombinogenic effect.
DOI